Biodel, Inc. is one of the companies that have joined the crusade against the illness. As a biopharmaceutical company, it innovates existing treatments for diabetes to make it safer and more effective. The development of the products of BIodel is leveraged on their proprietary formulation technologies. Their insulin formulations are programmed to be more rapid-acting compared to those regular drugs in the market. These formulations are available for both Type 1 and Type 2 diabetes patients. By improving the formulations of these existing drugs, the company is able to create more potent and fast acting medications that could save thousands of lives.
There are several products in the pipeline of development for treatment for diabetes. These medications are in various phases of clinical studies and include the Concentrated Ultra-Rapid-Acting Insulin, RHI-Based Ultra-Rapid-Acting Insulin, Analog-Based Ultra-Rapid-Acting Insulin and Glucagon. The latter is considered as a life saver for those patients suffering from severe hypoglycemia or those with very low levels of glucose in their blood. Anyone is capable of administering this medication as a rescue treatment. The business continues to develop these diabetes drugs in high hopes that one day, they will be able to make an impact on the lives of the millions who are suffering from this disease.
Biodel continues to compete against companies like Novo Nordisk, Eli Lilly, MannKind COrporatio and Halozyme Therapeutics, Inc. It is in Danbury, Connecticut that the company holds its corporate office. As a publicly traded company, common stocks of the business are marketed on the NASDAQ, using the ticker symbol BIOD.